Home › NDC Lookup › RxCUI directory › RxCUI 2280737

Trastuzumab-qyyp 21 MG/ML Injectable Solution [Trazimera] — RxCUI 2280737

RxNorm drug concept · Semantic branded drug
RxCUI 2280737 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2280737
Official nameTrastuzumab-qyyp 21 MG/ML Injectable Solution [Trazimera]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asTrazimera 21 MG/ML Injectable Solution; Trazimera 420 MG in 20 mL Injectable Solution; Trazimera 420 MG per 20 ML Injectable Solution
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)5,064 prescriptions · 32 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Trastuzumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Trastuzumab is used for more than just breast cancer. It treats HER2-positive breast cancer — both early-stage (after surgery) and metastatic (spread) breast cancer. It's also appr...
  • What exactly is trastuzumab used for — is it just for breast cancer?
  • No, trastuzumab is not a pill. It's given as an IV infusion — a drip into a vein — at your cancer center or infusion clinic. Your very first infusion is given slowly over 90 minute...
  • How will I receive this medication? Do I take it as a pill?
📖 Read our full Trastuzumab Injection guide →

🕸️ Concept Web — How Trastuzumab-qyyp 21 MG/ML Injectable Solution [T... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Trastuzumab-qyyp 21 MG/ML Injectable Solution [Trazimera] RxCUI 2280737

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Trastuzumab 224905
    • Trastuzumab-qyyp 2280730
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Trazimera 2280733
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Trastuzumab Injectable Solution 377216
    • Trastuzumab-qyyp Injectable Solution 2649137
    • Trastuzumab Injectable Product 1162762
    • Trastuzumab-qyyp Injectable Product 2661052
    • Trastuzumab Injectable Solution [Trazimera] 2280735
    • Trastuzumab-qyyp Injectable Solution [Trazimera] 2658192
    • Trazimera Injectable Product 2280736
    • Injectable Solution 316949
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Trastuzumab-qyyp 21 MG/ML Injectable Solution SCD · 2280732
  • Trastuzumab-qyyp 21 MG/ML SCDC · 2280731
  • Trastuzumab Injectable Solution SCDF · 377216
  • Trastuzumab-qyyp Injectable Solution SCDFP · 2649137
  • Trastuzumab Injectable Product SCDG · 1162762
  • Trastuzumab-qyyp Injectable Product SCDGP · 2661052

Brand-Name Concepts

  • Trastuzumab-qyyp 21 MG/ML [Trazimera] SBDC · 2280734
  • Trastuzumab Injectable Solution [Trazimera] SBDF · 2280735
  • Trastuzumab-qyyp Injectable Solution [Trazimera] SBDFP · 2658192
  • Trazimera Injectable Product SBDG · 2280736
  • Trazimera BN · 2280733

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2280737 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00069-0305-01 1 KIT in 1 KIT (0069-0305-01) * 20 mL in 1 VIAL, MULTI-DOS... Trazimera Pfizer Laboratories Div Pfizer Inc 2020-02-24
00069-0308-01 1 VIAL in 1 CARTON (0069-0308-01) / 7.15 mL in 1 VIAL Trazimera Pfizer Laboratories Div Pfizer Inc 2021-03-10
Observed labelers: Pfizer Laboratories Div Pfizer Inc (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
Q5116 Inj., trazimera, 10 mg 2 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.